TABLE 3.
Effects of different diuretic types (thiazide diuretics vs. loop diuretics) on the risks of all‐cause mortality, cardiovascular death, and cerebrovascular death in rheumatic heart disease patients with different diuretic application approaches (intermittent diuretics use or continuous diuretics use) a
| Clinical outcomes | Effect size for a change of | IDU | CDU | ||
|---|---|---|---|---|---|
| Effect size (95% CI) | P value | Effect size (95% CI) | P value | ||
| All‐cause mortality | TDs (ref.) vs. LDs | 0.31 (0.09–1.13) | 0.076 | 1.80 (1.09–2.99) | 0.023 |
| CVD | TDs (ref.) vs. LDs | 0.16 (0.02–1.57) | 0.116 | 1.89 (1.04–3.44) | 0.037 |
| Cerebrovascular death | TDs (ref.) vs. LDs | 0.22 (0.03–1.95) | 0.175 | 1.14 (0.16–8.02) | 0.896 |
CDU, continuous diuretics use; CI, confidence interval; CVD, cardiovascular death; IDU, intermittent diuretics use; LDs, loop diuretics; TDs, thiazide diuretics.
a
Model 4: it is the same as Model 1 with exception of types of diuretics.